BB Biotech

BB Biotech is an equity fund managed by Bellevue Asset Management, with its headquarters in Schaffhausen, Switzerland. Established in 1993, the fund specializes in investing in publicly traded companies within the biotechnology sector, focusing on those engaged in the development and commercialization of innovative medications and diagnostics. BB Biotech employs a fundamental analysis strategy to curate its portfolio, targeting firms with established products that demonstrate significant value for the healthcare system. As one of the largest investors in biotechnology, it emphasizes a long-term investment horizon and selectively screens potential investments. The fund generates key revenue from various markets, notably the Netherlands.